KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Equity Ratio (2010 - 2026)

Acadia Pharmaceuticals' quarterly Equity Ratio came in at 0.78 in Q1 2026, up 15.05% year-on-year from 0.68 in Q1 2025, and down 0.91% quarter-over-quarter from 0.78 in Q4 2025.

Acadia Pharmaceuticals has reported Equity Ratio for 17 years, with the latest figure at 0.78 in Q1 2026.

  • For the quarter ending Q1 2026, Equity Ratio rose 15.05% year-over-year to 0.78; the trailing twelve-month figure through Mar 2026 stood at 0.78 (up 15.05% YoY), and the FY2025 full-year result was 0.78, up 27.19% from the prior year.
  • Equity Ratio for Q1 2026 stood at 0.78, down from 0.78 in the prior quarter.
  • The five-year high for Equity Ratio was 0.78 in Q4 2025, with the low at 0.54 in Q1 2024.
  • Average Equity Ratio over 5 years is 0.65, with a median of 0.67 recorded in 2025.
  • Year-over-year, Equity Ratio fell 19.85% in 2023 and advanced 27.19% in 2025.
  • Tracing ACAD's Equity Ratio over 5 years: stood at 0.68 in 2022, then fell by 15.37% to 0.58 in 2023, then advanced by 7.02% to 0.62 in 2024, then increased by 27.19% to 0.78 in 2025, then fell by 0.91% to 0.78 in 2026.
  • The last three Equity Ratio figures came in at 0.78 (Q1 2026), 0.78 (Q4 2025), and 0.69 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 0.04
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - 0.42
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 0.73
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 0.77
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 0.21
10 Acadia Pharmaceuticals 3.69 Bn 2.84 Bn 243.27 Mn 0.78

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.78
Dec 31, 2025 0.78
Sep 30, 2025 0.69
Jun 30, 2025 0.67
Mar 31, 2025 0.68
Dec 31, 2024 0.62
Sep 30, 2024 0.59
Jun 30, 2024 0.57
Mar 31, 2024 0.54
Dec 31, 2023 0.58
Sep 30, 2023 0.57
Jun 30, 2023 0.62
Mar 31, 2023 0.57
Dec 31, 2022 0.68
Sep 30, 2022 0.71
Jun 30, 2022 0.71
Mar 31, 2022 0.71
Dec 31, 2021 0.77
Sep 30, 2021 0.79
Jun 30, 2021 0.78
Mar 31, 2021 0.77
Dec 31, 2020 0.80
Sep 30, 2020 0.82
Jun 30, 2020 0.87
Mar 31, 2020 0.85
Dec 31, 2019 0.89
Sep 30, 2019 0.90
Jun 30, 2019 0.84
Mar 31, 2019 0.83
Dec 31, 2018 0.89
Sep 30, 2018 0.84
Jun 30, 2018 0.84
Mar 31, 2018 0.87
Dec 31, 2017 0.87
Sep 30, 2017 0.91
Jun 30, 2017 0.91
Mar 31, 2017 0.91
Dec 31, 2016 0.92
Sep 30, 2016 0.94
Jun 30, 2016 0.93
Mar 31, 2016 0.95
Dec 31, 2015 0.90
Sep 30, 2015 0.93
Jun 30, 2015 0.93
Mar 31, 2015 0.94
Dec 31, 2014 0.95
Sep 30, 2014 0.97
Jun 30, 2014 0.97
Mar 31, 2014 0.98
Dec 31, 2013 0.96
Sep 30, 2013 0.91
Jun 30, 2013 0.88
Mar 31, 2013 0.77
Dec 31, 2012 0.78
Sep 30, 2012 0.74
Jun 30, 2012 0.58
Mar 31, 2012 0.66
Dec 31, 2011 0.73
Sep 30, 2011 0.76
Jun 30, 2011 0.79
Dec 31, 2010 0.77